Inflammatory Disease

Chronic Inducible Urticaria Patients Wait Two Years for Diagnosis

<![CDATA[CIndU Patient Demographics: Disease Duration, Diagnostic Delay, and Quality of Life]]>
kumarsu6745_ / pixabay

Patients with chronic inducible urticaria (CIndU, hives triggered by stimuli such as cold, pressure or heat) waited about two years for a correct diagnosis and cycled through an estimated six providers before reaching it, according to baseline data discussed by clinicians reviewing a trial cohort. The same data show that perhaps half of participants had ever used antihistamines, and fewer than that had undergone up-titration (increasing the dose above the standard label level).

Dr. Dasilva opened the discussion, "CIndU Patient Demographics: Disease Duration, Diagnostic Delay, and Quality of Life," with the cohort's baseline characteristics. Disease chronicity stood out. Cold urticaria patients carried the longest histories, while symptomatic dermatographism (a whealing response to firm skin stroking) and cholinergic urticaria (heat- and exercise-triggered hives) patients also reported many years of disease and substantial prior antihistamine use.

What surprised the clinicians?

Dasilva noted one unexpected finding: not every participant had used antihistamines before enrollment. He suggested some patients may not know these drugs can treat their condition at all. The gap implies a real-world education problem, not merely a dosing problem.

Dr. Finklea said the demographics match what dermatologists see in clinic: typically middle-aged women. The cholinergic group was the exception, skewing male and younger. She agreed with the antihistamine figures and framed the shortfall in up-titration as an opportunity to optimize standard therapy before moving patients on to other treatments.

Why does diagnosis take two years?

Finklea called the long disease duration remarkable but consistent with clinical experience. Patients bounce among providers during the first years, she said, and the historical record makes the reason plain: patients often did not photograph their reactions or give clear histories, which made accurate diagnosis difficult.

Dasilva said the situation has improved over the last decade. Yet structural barriers remain. Finklea pointed out that most clinics lack provocation tests, so outside dermatographism and perhaps cold urticaria, diagnosis is hard. Clinics do not have exercise bikes, she noted, and improvising tests is challenging.

How much does the disease affect quality of life?

Dasilva highlighted the Dermatology Life Quality Index (DLQI, a 0–30 questionnaire measuring skin disease impact on daily life), which documented the disease's effect in this cohort. Finklea confirmed the scores are high.

She added a cautiously optimistic observation: clinicians increasingly administer quality-of-life indices in the office. That shift, she said, shows practitioners are starting to listen to how patients actually experience their disease.

What comes next?

The series continues with "Provocation Testing for CIndU: Bringing Trial Tools Into Clinical Practice," which will examine whether the trial's design reflects the clinic and which test tools could realistically be deployed there. If the answer is a workable provocation toolkit, the two-year diagnostic delay these patients endure may become a target rather than a fixed cost.

Source: dermatologytimes.com

Share this article:

Amara Osei

Show full bio

Correspondent covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Amara Osei →

Related articles

« Previous articleNext article »